Introduction
One of the contributing factors to high mortality rate from prostate cancer is the extreme resistance of malignant prostate cells to apoptosis induced by radioand chemotherapy. Thus, the specific induction of apoptosis in prostate carcinoma (PC) cells could play a strategic role for PC treatment.
Nuclear factor kappa-B (NF-kB) transcription factor mediates one of the central signaling pathways, protecting cells from apoptotic death (Karin and Lin, 2002; Kucharczak et al., 2003) . NF-kB also regulates tumor development through transcriptional regulation of a wide variety of genes that encode antiapoptotic proteins, cell cycle-related proteins, proteins involved in angiogenesis, invasion and metastasis (Ghosh and Karin, 2002; Shishodia and Aggarwal, 2004) .
The active NF-kB complex is a homo-or heterodimer composed of proteins from the NF-kB/Rel family: NFkB1 (p50/105), NF-kB2 (p52/100), RelA (p65), RelB and c-Rel (Verma et al., 1995; Baldwin, 1996) . In nonstimulated cells, NF-kB resides in the cytoplasm in a complex with the inhibitor protein, collectively called IkB. Several inhibitor of nuclear factor kappa-B (IkB) proteins have been identified, including IkBa, IkBb and IkBe, and proteins p105 and p100, the precursor molecules for NF-kB proteins p50 and p52, respectively (Verma et al., 1995; Whiteside and Israel, 1997) . Most agents that activate NF-kB employ a common pathway that involves the phosphorylation of the two N-terminal serines in IkB molecules IkBa, IkBb, IkBe, and the subsequent ubiquitination and degradation of IkB proteins by the 26S proteasome (Whiteside and Israel, 1997) . Signal-induced phosphorylation of IkB is executed by a large 900 kDa IkB kinase (IKK) complex, containing two major IkB kinases (IKK) IKKa and IKKb, as well as several scaffolding proteins (Karin and Ben-Neriah, 2000) .
There is mounting evidence that constitutive NF-kB activation is a common feature of a variety of hematological and solid tumor cell lines and tumors (Rayet and Gelinas, 1999; , and that constitutive activation of NF-kB suppresses the susceptibility of tumor cells to apoptosis induced by radio-and chemotherapy. We and others showed previously that NF-kB was constitutively activated in androgen-independent PC cell lines due to the constitutive upregulated activity of IKK kinases (Chen and Sawyers, 2002; Gasparian et al., 2002; Suh et al., 2002; Zerbini et al., 2003) . NF-kB inhibition with a IkBa super-repressor in PC cells led either to apoptosis or to sensitization to apoptosis induced by tumor necrosis factor alpha (TNFa) and some other treatments (Herrmann et al., 1997; Muenchen et al., 2000; Gasparian et al., 2002) . Most importantly, inhibition of NF-kB with an IkBa superrepressor in PC cells suppressed both growth and development of metastatic lesions by those cells in vivo when they were injected into prostate ortotopically (Huang et al., 2001) . Overall, these data suggest that NF-kB signaling pathway is critically important for PC cell growth and the development of metastases in animal models. Thus, NF-kB represents an important target for PC treatment, especially when NF-kB inhibition is used in combination with other proapoptotic chemotherapeutical drugs.
The results of immunostaining of human PCs for major NF-kB protein RelA/p65 are in line with the data obtained in PC cells in vitro. We and others showed that p65 has nuclear localization in a significant number of epithelial cells in prostate tumors, especially in hormone-refractory metastatic PCs (Gasparian et al., 2002; Ross et al., 2004; Sweeney et al., 2004) . Nuclear localization of p65 strongly suggests that NF-kB is activated in human PCs, and that constitutive activation of this key antiapoptotic factor could significantly contribute to the resistance of hormonerefractory PCs to apoptosis induction during chemoand radiotherapy.
There are several pharmacological approaches to target NF-kB. They include repression of NF-kB transactivation potential, stabilization of IkB inhibitors by proteasome inhibitors and, more recently, inhibition of upstream IKK kinases (Karin, 2004) . The unique properties of IKKb among other serine-threonine kinases allowed successful development of specific IKKb inhibitors at Millennium Pharmaceuticals Inc. (Hideshima et al., 2002; Castro et al., 2003; Lam et al., 2005) and other companies (Burke et al., 2003; Kishore et al., 2003; Ziegelbauer et al., 2005) . In the presented work, we studied the effect of the small-molecule IKK inhibitor PS1145 on the status of NF-kB in PC cells, PC cell growth, sensitivity of PC cells to apoptosis and on the invasion capability of PC cells. We demonstrated that PS1145 efficiently inhibited both basal and induced NF-kB activity in PC cells. PS1145 induced apoptosis in PC cells and significantly sensitized PC cell lines to TNF-a-induced apoptosis in a caspase 3/7-dependent manner. In addition, we found that preincubation with PS1145 inhibited PC cell growth and the invasion activity of highly invasive PC3-S cells in invasion chamber assay.
Results

Expression of activated IKKs in PCs
Our previous studies as well as data by others revealed that androgen-independent PC cells maintain the high level of NF-kB basal activity due to constitutive IKK activation (Gasparian et al., 2002) . To extend our in vitro observations, we performed immunostaining of 10 high-grade PCs (Gleason score 7-9) with Ab against IKKa/b phosphorylated at Ser176/180. It is known that activation of IKKa and IKKb requires their phosphorylation at those specific serines in the activation loop of IKK kinases (Karin and Ben-Neriah, 2000; Huynh, 2000) . As shown in Figure 1 , activated IKKa/b were strongly expressed in the cytoplasm of epithelial cells in PCs. This finding suggests that IKK kinases are indeed constitutively active in prostate cells in tumors and correlates well with nuclear localization of p65/RelA and NF-kB activation in PCs previously described in our work and in other publications (Gasparian et al., 2002; Ross et al., 2004; Sweeney et al., 2004) .
PS1145 inhibited basal and induced IkBa phosphorylation and NF-kB activity in androgen-independent PC cell lines We and others have shown that NF-kB is constitutively activated in androgen-independent PC cell lines due to the constitutive upregulated activity of IKK kinases. The IkBa protein, a key substrate for IKKa/IKKb kinase complex, is constitutively phosphorylated in PC3 and DU145 cells (Gasparian et al., 2002) . Despite the high constitutive level of NF-kB activity, androgenindependent PC cells appeared to be highly sensitive to diverse NF-kB inducers (Gasparian et al., 2003) . For example, DU145 cells are highly responsive to TNF-a and lipopolysaccharide (LPS), while PC3 cells are highly responsive to LPS and TPA, but not to TNF-a. Based on these findings, we selected different NF-kB inducers to study the effect of PS1145 on NF-kB activation in PC3 and DU145 cells.
To evaluate the effect of the IKK inhibitor PS1145 on phosphorylation of IkBa, we performed Western blot analysis using whole-cell proteins from DU145 or PC3 cells treated with PS1145 at concentrations 0.5-20 mM for 2-24 h. We found that the PS1145 effect was especially pronounced when cells were incubated with this IKK inhibitor at concentrations 10-20 mM (Figure 2a and data not shown). The significant decrease of IkBa constitutive phosphorylation was revealed 12-16 h after treatment in both DU145 and PC3 cells (Figure 2a and b and data not shown). Furthermore, IkBa phosphorylation was almost completely blocked when cells were incubated with PS1145 for 24 h (Figure 2a and b) . However, in PC3 cells decrease in IkBa phosphorylation 24 h after PS1145 treatment coincided with inhibition of total IkBa expression at this time point (see below), suggesting that the relative level of inhibition of IkBa phosphorylation (ratio P-IkBa:total IkBa) in PC3 cells was similar after 16 and 24 h of treatment with PS1145. PS1145 also strongly inhibited induced IkBa phosphorylation. Indeed, preincubation of PC cells with PS1145 for 3 h significantly inhibited IkBa phosphorylation induced by short treatments with different compounds such as TNF-a, LPS and TPA (Figure 3 and data not shown). In addition, we found a stable strong effect of long cell pretreatment with PS1145 (24 h) on TNF-a-induced IkBa phosphorylation in DU145 cells (Figure 2b) . Importantly, the similar decrease in IkBa phosphorylation was observed in PC3 cells stably infected with lentivirus expressing IKKb dominantnegative (d.n.) mutant (Figure 2a , last lane).
We have to mention that treatment of PC3 cells with PS1145 for 16-24 h as well as the transfection with exogenous IKKb d.n. mutant has resulted in the decreased level of total IkBa. This reflects the dramatic downregulation of IkBa gene transcription in PC3 cells under this treatment (Figure 5b ) and will be discussed later. PS1145 did not affect IkBa expression in DU145 cells (Figure 2b ).
In our next experiments, we examined PS1145 effect on NF-kB DNA binding in PC cells. The effect of PS1145 on different steps of NF-kB activation was dosedependent, and more pronounced when we used PS1145 at the concentration of 20 mM (data not shown). As shown in Figure 3 , pretreatment of DU145 cells with PS1145 for 3 h strongly inhibited IkBa phosphorylation, delayed the degradation of IkBa and nuclear translocation of p65 induced by TNF-a, and accordingly significantly decreased the effect of TNF-a on kB DNA binding. Similarly, PS1145 inhibited IkBa phosphorylation, degradation, p65 nuclear translocation and NF-kB binding induced by LPS (Figure 3b ) and TPA (data not shown) in PC3 cells.
To evaluate the effect of PS1145 on gene transcription, we used transient transfection of PC cells with a 5 Â kB luciferase reporter. To induce NF-kB-dependent transcription of reporter gene, PC cells were transfected with exogenous IKKb or treated with the appropriate kB inducer: TNF-a (for DU145 cells) or LPS (for PC3 cells) for 24 h. NF-kB activity induced by TNF-a, LPS and exogenous IKKb was strongly inhibited by PS1145 in both PC cell lines (Figure 4a and b) . In addition, PS1145 significantly blocked basal NF-kB transcriptional activity in PC3 cells (Figure 4b) .
To study the effect of PS1145 on the transcription of endogenous kB-responsive genes, we used Northern blot analysis of IkBa expression. IkBa gene has five kB sites in its promoter, and is tightly regulated by NF-kB in different cells (Ito et al., 1994) . We showed previously that the level of steady-state IkBa expression directly correlated with the level of constitutive NF-kB activity in different PC cell lines (Gasparian et al., 2002) . The results of Northern blotting demonstrated that treatment with PS1145 (20 mM) for 24 h blocked both basal and inducible expression of IkBa in PC cells (Figure 5a and b). The effect of PS1145 on IkBa expression was dose-and time-dependent (data not shown) with maximum IkBa expression blockage after 24 h exposure to PS1145. 
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Overall, the results of Northern blot analysis correlated well with the data obtained by Luciferase reporter assay and electrophoretic mobility shift assay (EMSA). We found that PS1145 strongly inhibited NF-kB activity in both PC cell lines irrespectively of the nature of the NF-kB inducer. Notably, the effect of PS1145 on basal NF-kB activity was revealed easier in PC3 cells despite the fact that PS1145 strongly inhibited basal IkBa phosphorylation in both PC cell lines.
PS1145 inhibited proliferation of DU145 cells
The effect of PS1145 on proliferation was assessed by several approaches in DU145 cells. As shown in Figure 6a , MTT test revealed 30-35% decrease in DU145 cell numbers 48-72 h after PS1145 treatment. BrdU labeling of DU145 cells confirmed the result of MTT test. The number of BrdU-positive cells (cells in S-phase) was decreased by 3273.25% in DU145 cell cultures treated with PS1145 for 72 h (Figure 6b ). The inhibition of proliferation was further confirmed by the decrease of Ki67 protein expression known to be present in cells in G1, S, G2 and M phases, but not in G0 phase of the cell cycle (data not shown). Therefore, we have shown that PS1145 caused significant inhibition of proliferation in DU145 cells.
PS1145 induces apoptosis in DU145 cells and increases their sensitivity to TNF-a
Long-term exposure to PS1145 was toxic for DU145 cells. To evaluate the effect of PS1145 on apoptosis in these cells, we measured caspase 3/7 activity, and used Western blot analysis to assess poly-(ADP-ribose) polypeptide (PARP) cleavage. As shown in Figure 7a , treatment of DU145 cells with PS1145 for 48 h resulted in strong activation of caspase 3/7 in a dose-dependent manner. Western blot analysis of caspase 3/7-dependent PARP cleavage also demonstrated that PS1145 induced apoptosis in DU145 cells 48-72 h after the beginning of the treatment (Figure 7b and c). Importantly, PS1145 sensitized DU145 cells to TNF-a-induced apoptosis: PARP cleavage and caspase 3/7 activation ( Figure 7b and c) were much more pronounced in DU145 cells treated with combination of TNF-a and PS1145. These data are in line with the previous observations that NFkB protects different cells, including PC cells, against apoptosis induced by TNF-a, and that NF-kB blockage by different genetic approaches results in cell sensitization to TNF-a (Muenchen et al., 2000; Gasparian et al., Figure 4 Effect of PS1145 on NF-kB transcriptional activity in PC cell lines. DU145 (a) and PC3 (b) cells were cotransfected with Â 5 kB FL reporter, pRNL-null (RL), pcDNA and with w.t. IKKb plasmids. Cells were treated with TNF-a (7 ng/ml), LPS (10 mg/ml), PS1145 (10 mM) or the combination PS1145 þ TNF-a or PS1145 þ LPS for 24 h. Luciferase activity was measured by dual luciferase assay. Data are shown as fold of inhibition or induction, calculated as FL/RL ratio for treated samples normalized against FL/RL ratio for control samples (controls are presented in the far left lanes in (a) and (b)).
Figure 5
Northern blot analysis of IkBa expression in PC cells after PS1145 treatment. DU1145 (a) and PC3 cells (b) were treated with TNF-a (7 ng/ml), PS1145 (10 mM) or the combination PS1145 þ TNF-a for 24 h. Northern blots (20 mg RNA/lane) were probed for expression of IkBa. Ethidium bromide gel staining (lower panels) was used for the verification of equal RNA loading.
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A Yemelyanov et al 2002; Orlowski and Baldwin, 2002; Shukla and Gupta, 2004) . Overall, our data indicate that the effect of PS1145 on PC cell growth and apoptosis develops after prolonged treatment (i.e. requires cell maintenance under the conditions when NF-kB is chronically inhibited), even though the significant NF-kB inhibition is achieved in 16 h.
PS1145 inhibited the invasion activity of PC3-S cells in vitro
It is known that DU145 cells do not possess high invasion and migration capability in in vitro and in vivo experiments. In contrast, several clones derived from the original PC3 cell line were reported to be highly invasive in animals and in invasion chambers in vitro. Thus, to study the effect of PS1145 on PC cell motility and invasiveness, we used a highly invasive PC3 clone PC3-S (Lindholm et al., 2000) . The cell invasiveness was studied using invasion assay of radioactively labeled cells. As shown in Figure 8 , PS1145 dramatically inhibited invasion of PC3-S cells in a dose-dependent manner. The effect was more pronounced if the cells were preincubated with PS1145 for 24 h. The inhibition of invasion by PS1145 was not due to PS1145 toxicity for PC3-S cells. PC3-S cells appeared to be rather resistant to the toxic effect of PS1145 evaluated by PS1145 effects on gene expression in PC cells NF-kB regulates a wide variety of genes that encode antiapoptotic proteins, cell cycle proteins, cytokines, proteins involved in cell-cell and cell-extracellular matrix (ECM) interactions and others. Thus, to address the mechanisms underlying the effects of PS1145 on PC cells, we performed semiquantitative RT-PCR analysis of the set of 21 genes known to be important for control of cell cycle, apoptosis and cell-cell and cell-ECM interactions (Toth et al., 1995; Glasgow et al., 2000; Catz and Johnson, 2001; Hinz et al., 2001; Gupta et al., 2002; Martone et al., 2003) . The gene selection was made after the comparison of database obtained by cDNA array analysis of global effect of PS1145 on gene expression in PC cells (these data are not shown in this paper, and are planned to be used for another research project) and the literature database for NF-kB-dependent genes (http://www.nf-kb.org). The list of selected genes is presented in Table 1 . The quantitative analysis of gene expression was performed by Agilent 2001 Bioanalyzer as described in Materials and methods.
As shown in Figures 9 and 10 , we found that the expression of nine out of 21 studied genes was significantly changed in DU145 cells treated with PS1145, especially after longer 72 h treatment. Figure 9 represents the agarose electrophoresis analysis of RT-PCR products. Figure 10 shows quantitative analysis of expression of all the selected genes ( Table 1) . As expected, the expression of well-known NF-kBdependent genes such as inhibitor of apoptosis (IAP)-1, IAP-2, cyclin D1, D2, interleukin (IL)-6 and IL-9 was significantly decreased in DU145 cells with inhibited NF-kB activity. The similar inhibition of those genes was found in PC3 cells (data not shown). The expression of three other apoptosis-related genes c-FLIP (CASP8 and FADD-like apoptosis regulator precursor, long isoform), XAF1-X-linked inhibitor of apoptosis protein (XIAP)-associated factor and cell death regulator AVEN was increased in both PC cell cultures, while we did not find any changes in expression of Bcl-2 and Bax. The relevance of those changes to apoptosis induced by PS1145 in PC cells will be discussed below. We also did not find significant changes in the expression of cyclin B1 and B2, and Cdks in PC cells, even though some of those cell cycle-related genes have been previously reported to be downregulated by NFkB inhibitors (Guttridge et al., 1999; Gupta et al., 2002) . Genes from the vascular endothelial growth factor (VEGF) family were differentially regulated in two PC cell lines: VEGF-C was significantly downregulated only in DU145 cells and VEGF-D was downregulated only in PC3 cells (Figure 10) . Overall, the antiapoptotic and antiproliferative effects of PS1145 correlated well with downregulation of IAP-1, IAP-2, cyclin D1 and D2.
It is known that cytokine IL-6 plays an important role in the growth of androgen-independent prostate tumor cells via autocrine and paracrine mechanisms (Giri et al., 2001; Zerbini et al., 2003; Culig et al., 2004) . To extend our finding on the inhibition of IL-6 gene expression by PS1145 in DU145 cells, we used ELISA assay to evaluate the amount of IL-6 protein secreted into the cell culture medium by DU145 cells treated with PS1145. As shown in Figure 11 , inhibition of IKK resulted in a significant decrease of IL-6 levels.
Effect of PS1145 treatment on cell signaling pathways The data obtained in our studies indicate that, despite the strong effect of PS1145 on NF-kB activity, its effect on proliferation and apoptosis in PC cells was more modest. This raised the question about the possible activation of some proproliferative, such as mitogenactivated protein kinase (MAPK) (Zerbini et al., 2003) , and antiapoptotic, such as Akt (Culig et al., 2004; Li et al., 2005) , signaling pathways in PC cells to compensate for NF-kB blockage. To assess the effect of PS1145 on Akt, MAPK and stress-activated protein kinase/Jun-N-terminal kinase (SAPK/JNK) signaling, we evaluated the levels of Akt, SAPK/JNK and dualspecificity mitogen-activated protein kinase kinase 1 
Discussion
There is mounting evidence that NF-kB activation is associated with tumorigenesis. NF-kB was found to be activated in human leukemias and lymphomas, lung and breast carcinomas, as well as in numerous cell lines of different origin (Rayet and Gelinas, 1999; . The chronic activation of NF-kB in tumor cells has been linked both to genetic changes and to epigenetic mechanisms. There are numerous reports indicating that upstream signaling pathways causing (or associated with) tumor development can activate NF-kB. Viral oncoproteins including Tax and EVB nuclear antigen are known to activate NF-kB through 
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interaction with IKK complex or some other mechanisms Orlowski and Baldwin, 2002) . NF-kB and IKK complex could be induced by activated oncogens Ras, Bcr-Abl, members of Rho protein family (Orlowski and Baldwin, 2002) . Production of numerous growth factors and cytokines that are strong activators of IKK complex, and whose expression is in turn NFkB-dependent, is typical for tumor cells (Orlowski and Baldwin, 2002; Zerbini et al., 2003; Greten and Karin, 2004) . Those cytokines, including IL-6 and growth factors, may contribute to the establishment of positive autocrine/paracrine loops of NF-kB activation in tumor cells (Giri et al., 2001; Zerbini et al., 2003; Culig et al., 2004) . There is also evidence that IKK-independent pathways, including p65 phosphorylation, can be involved in NF-kB constitutive activation in tumor cells (Viatour et al., 2005) . Recently, we and others found that NF-kB is activated in androgen-independent PC cells and in prostate tumors, where NF-kB has nuclear localization in at least 15% of cells (Palayoor et al., 1999; Gasparian et al., 2002; Ross et al., 2004; Sweeney et al., 2004) . The major mechanism of NF-kB activation in PC cell lines involves the aberrant activation of IKK complex, resulting in increased phosphorylation and instability of IkB inhibitor proteins (Gasparian et al., 2002) . Importantly, in this work using immunostaining with antibodies against activated, phosphorylated IKKs, we showed for the first time that IKK complex is also activated in PC samples. Thus, IKKs, especially IKKb that is critical for NF-kB activation, represent a novel important target for NFkB blockage in PC and other tumor cells. Very recently, several pharmaceutical companies have started working on the design of potent orally active IKKb inhibitors (Burke et al., 2003; Kishore et al., 2003; Baxter et al., 2004; Murata et al., 2004; Ziegelbauer et al., 2005) . PS1145 is one of these highly specific IKK inhibitors (ICo0.1 mM) recently developed by Millenium Pharmaceuticals, Inc. (Hideshima et al., 2002; Lam et al., 2005) .
In this work, we developed a comprehensive picture of the effects of PS1145 on NF-kB activity, growth, sensitivity to apoptosis and invasiveness of PC cells. We first demonstrated that pretreatment with PS1145 (10-20 mM) efficiently inhibited both basal and induced NF-kB activity in PC cells. Then we studied the major biological responses of PC cells resulting from NF-kB inhibition. We showed that PS1145 inhibited proliferation of DU145 cells when cells were incubated with IKK inhibitor for 48-72 h. These data are in line with the previous findings indicating that NF-kB is an important regulator of cell proliferation, and its effect is mediated through regulation of expression of cyclins (especially cyclin D1), possibly CDK/CKI genes, and some other cell cycle-related genes, for example, c-myc. Our study has revealed that PS1145 significantly inhibited cyclin D1 and D2 expression in PC cells, but did not affect the expression of cyclin B1, B2, cdk6, cdk4, cdc2, cdc5 and cdc6. Relatively modest inhibition of PC cell proliferation by PS1145 correlates well with the results obtained 
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A Yemelyanov et al in multiple myeloma cells treated with the same IKK inhibitor (Hideshima et al., 2002) , and in PC-3 cells transfected with IkBa super-repressor (Huang et al., 2001) , and may reflect the existence of compensatory mechanisms that counteract NF-kB blockage in PC cells. Indeed, we found that Raf/Mek1/2/Erk1/2 kinases were strongly activated in DU145 cells by PS1145. This suggests that simultaneous inhibition of NF-kB and MAP kinase cascade may result in more profound inhibition of PC cell proliferation. A key role of NF-kB in cell protection against diverse apoptotic stimuli including chemo-and radiotherapy is very well known. The antiapoptotic NF-kB-regulated genes include genes that encode Bcl-2-like proteins (A1/ Bfl1, Bcl-X l and Nr13), IAP proteins -IAP-1, IAP-2, X-IAP-1 and others (Barkett and Gilmore, 1999) . In our experiments, PS1145 itself triggered modest apoptosis in DU145 cells treated for 72 h or longer. Most importantly, PS1145 treatment significantly sensitized relatively resistant DU145 cells to TNFa-induced apoptosis. These data correlate well with the previous findings that NF-kB blockage by overexpression of nondegradable IkBa mutant may result in apoptosis or in sensitization to TNF-a-induced apoptosis in PC cells. Further analysis of mechanisms of apoptotic death induced by PS1145 in PC cells revealed the central role of caspase 3/7 in this process. Indeed, we found that PS1145 induced caspase 3/7 activation and, consequently, increased cleavage of PARP, a target protein for caspase 3/7. In turn, the activation of caspase 3/7 correlated with the decreased expression of its inhibitors, IAP-1 and IAP-2 after PS1145 treatment. Moreover, our data indicated the role of XIAP-associated factor-1 (XAF1), an antagonist of another inhibitor of caspase 3/7, X-IAP. We found that XIAF1 expression was significantly increased in PC cells treated with PS1145. On the contrary, we did not find changes in the expression of genes involved in mitochondrial apoptosis (Abraham and Shaham, 2004; Rapp et al., 2004) . Unexpectedly, certain antiapoptotic genes have been activated in PC cells after PS1145 treatment. For example, the expression of genes that encode caspase 8 (FLICE) inhibitory protein c-FLIP (long FLIP isoform), and especially cell death regulator Aven was increased in DU145 cells treated with PS1145. Aven was recently shown to bind both Bcl-x(L) and the caspase 9 regulator Apaf-1, thus inhibiting mitochondrial apoptosis (Chau et al., 2000; Figueroa et al., 2004; Peter, 2004) . Interestingly, the effect of PS1145 on Aven expression was especially pronounced in PC3 cells more resistant to PS1145-induced apoptosis, than in DU145 cells (data not shown). This may potentially explain the known higher resistance of PC3 cells to apoptosis induced by NF-kB blockage.
As we mentioned, the specific pharmacological IKK inhibitors have been developed only recently. Thus, the information about their effect on tumor cell behavior is very limited. PS1145 was recently tested in multiple myeloma cells (Hideshima et al., 2002) . Another novel IKK inhibitor, BMS-345541 (Burke et al., 2003) , was studied in human melanoma cells (Yasui et al., 2003) .
Overall, the effects of IKK inhibitors in other tumor cells were similar to our findings in PC cells. Both IKK inhibitors decreased tumor cell proliferation in vitro, and either induced apoptosis or sensitized tumor cells to apoptosis induced by TNF-a. BMS-345541 also inhibited melanoma cell growth in vivo as xenografts in nude mice. Interestingly, in both cell types, IKK inhibition has resulted in abrogation of paracrine growth loops, mediated in multiple myeloma cells by IL-6, and in melanoma cells by chemokine CXCL1. Aberrant expression of IL-6 has been implicated in PC progression and resistance to chemotherapy (Giri et al., 2001; Zerbini et al., 2003; Culig et al., 2004) . IL-6 is highly expressed in androgen-independent PC cell lines, and has been shown to function as an important growth factor in PC cells, possibly also through autocrine growth loop (Zerbini et al., 2003) . Importantly, treatment of PC cells with PS1145 resulted in significant decrease of IL-6 gene expression and decreased concentration of IL-6 protein in cell culture medium, suggesting that PS1145 affects positive growth loop mediated by IL-6 in PC cells.
In conclusion, the presented results obtained in PC cell cultures suggest that constitutively active antiapoptotic and proproliferative NF-kB signaling represents a rational target for PC treatment, especially in combination with some other proapoptotic chemotherapeutical drugs. The development of IKK inhibitors that more specifically block NF-kB signaling than all other agents including proteasome inhibitors will be very helpful to block NF-kB as a novel anticancer strategy in clinics.
Materials and methods
Cell cultures and treatments DU145 and PC3 cells were purchased from the American Tissue Culture Collection (Rockville, MD, USA). DU145 and PC3 cells were cultured in RPMI 1640 medium (Gibco BRL Life Technologies, Rockville, MD, USA) supplemented with 10% FBS (HyClone, Logan, UT, USA), sodium pyruvate (1 mM, Sigma Chemical Co., St Louis, MO, USA) and antibiotics (Gibco BRL Life Technologies, Rockville, MD, USA). The following reagents were used for cell treatments: PS1145 (Millenium Pharmaceuticals, Inc., Boston, MA, USA), LPS, DMSO and TNF-a from R&D Systems (Minneapolis, MN, USA). PS1145 was dissolved in DMSO, and stock solution was stored at À201C. PC3 cells stably expressing d.n. IKKb mutant tagged with FLAG were generated using lentivirus system from Invitrogen Corporation (Carlsbad, CA, USA) following the manufacturer's protocol. Antibiotic blasticidin was used at concentration of 6 mg/ml to select for d.n. IKKb-expressing clones. The d.n. IKKb expression was confirmed using anti-FLAG antibodies (Sigma Chemical Co., St Louis, MO, USA) and anti-IKKa/b antibodies (Santa Cruz Biotechnology, Santa Cruz, CA, USA) by Western blotting and immunostaining (data not shown). We used in our work pulled PC3-d.n. IKKb cell cultures.
Preparation of cellular extracts and electrophoretic mobility shift assay Nuclear and cytosolic proteins were isolated as described previously (Lyakh et al., 2000) . The binding reaction for EMSA contained 10 mM HEPES (pH 7.5), 80 mM KCl, 1 mM EDTA, 1 mM EGTA, 6% glycerol, 0.5 mg of poly(dI-dC), 0.5 mg of sonicated salmon sperm DNA, g-32 P-labeled (2-3 Â 10 5 c.p.m.) double-stranded kB-consensus oligonucleotide (Promega Corp., Madison, WI, USA), g-32 P-labeled (2-3 Â 10 5 c.p.m.) and 5-10 mg of the nuclear extract. DNA-binding reaction was performed at room temperature for 30 min in a final volume of 20 ml. DNAprotein complexes were analysed on 6% DNA retardation gels (Novex, Carlsbad, CA, USA). Dried gels were subjected to radiography.
Western blot analysis
Whole-cell protein extracts were prepared using RIPA buffer as described elsewhere (Rosenberg, 1996) . Proteins were resolved by electrophoresis on 10% SDS-PAGE and transferred to Immobilon-P membrane (Millipore Corporation, Bedford, MA, USA). Anti-phospho-Mek1/2, anti-phosphoErk1/2, anti-phospho-Akt, anti-phospho-SAPK/JNK, antiphospho-c-Raf and anti-phospho-Ser32 IkBa and anti-PARP Abs were from Cell Signaling Technology, Inc. (Beverly, MA, USA); anti-p65 and anti-IkBa antibodies were from Santa Cruz Biotechnology (Santa Cruz, CA, USA). Membranes were blocked with 5% non-fat milk in TBST buffer and incubated with primary antibodies overnight at 41C. Peroxidase-conjugated anti-rabbit or anti-mouse IgG (Sigma Chemical Co., St Louis, MO, USA) were used as secondary antibodies. ECL Western blotting reagent (Amersham Pharmacia Biotech, Sweden) was used for protein detection. To verify for equal amounts of proteins loaded and transferred, the membranes were stained with Ponceau Red.
Transfection of PC cells and luciferase activity
The following constructs were used for transfections: kBluciferase reporter -Firefly luciferase (FL) under a 5 Â kB promoter kindly provided by Dr WC Greene (Gladstone Institute for Virology and Immunology, University of California, San Francisco, CA, USA); pRL-null constructRenilla luciferase (RL) under a minimal promoter (Promega Corp., San Luis Obispo, CA, USA); pcDNA3.1-CMV-IKKb wild type (w.t.) (kindly provided by Dr F Mercurio, Signal Pharmaceutical, Inc., San Diego, CA, USA). PC cells were plated onto 12-well plates and at 50% confluency were cotransfected with indicated plasmids using Effectene reagent (Qiagen Inc., Valencia, CA, USA) according to the manufacturer's protocol. The amount of each plasmid DNA was 0.5 mg/well. Prostate cells were harvested 36 h after the transfection and the Luciferase activity was measured by dual luciferase assay (Promega Corp., San Luis Obispo, CA, USA) on a TD20/20 Turner luminometer (Turner Design Instruments, Sunnyvale, CA, USA). When necessary, before transfections, cells were pretreated with PS1145 (10 mM) and/ or TNF-a (7 ng/ml) or LPS (1.5 mg/ml). FL activity was normalized against RL activity to equalize for transfection efficacy.
Northern blot analysis
Total RNA from freshly harvested cells was isolated by TRI reagent (Molecular Research Center, Inc., Cincinnati, OH, USA) and subjected to Northern blotting. In all, 20 mg of total RNA was resolved in 1% agaroseÀ6% formaldehyde gel. The RNA was transferred to nylon membranes and probed for IkBa. The DNA probe was prepared by random-primed reactions using the complete coding sequence of human IkBa cDNA (ATCC, Rockville, MD, USA).
RT-PCR Two-step RT-PCR reaction using reverse transcriptase MLV-RT with random primers and PCR-Supermix (both from Invitrogen Corp., Carlsbad, CA, USA) with appropriate PCR primers was performed using total RNA isolated by RNAeasy mini kit (Qiagen Inc., Valencia, CA, USA). PCR primers were designed using Primer-Bank database (http://pga.mgh.harvard. edu/primerbank/) and RTPrimerDB Real Time PCR Primer and Probe Database (http://medgen.ugent.be/rtprimerdb/ index.php). PCR products were analysed by electrophoresis in 1.5% agarose gel. The actual amount of PCR product was measured by an Agilent 2001 Bioanalyzer and normalized to the amount of GAPD PCR product. For quantitative analysis, the data are represented as the ratio of GAPD-normalized amount of PCR product in PS1145-treated cells to the GAPDnormalized amount of PCR product in control cells.
IL-6 secretion DU145 cells were plated at 5000 cells/well in BD356640 poly-D lysine 96-well plates (Beckton Dickenson, Franklin Lakes, NJ, USA). Cells were incubated with PS1145 at increasing concentrations for 48 h. IL-6 level in tissue culture media was measured using Quantikine Assay for human IL-6 (R&D Systems, Minneapolis, MN, USA) according to the manufacturer's protocol using Wallace Victor 2 1420 luminometer.
Assessment of proliferation
Cell proliferation was assessed using None-Radioactive Cell Proliferation Assay (MTS test) from Promega Corporation (San Luis Obispo, CA, USA) and bromodeoxyuridine (BrdU) cell labeling using immunofluorescence. For both tests PC were plated onto 12-well plates (20 Â 10 3 cells/well), and cultured for 24-72 h in the presence of 10 mM PS1145. Every 24 h fresh complete media containing 10 mM PS1145 was added to the cells. For MTS test each group of cells was plated in triplicate. The MTS reagent was prepared and used according to the manufacturer's protocol. Optical density of the samples was measured on a plate reader at 490 nm.
For BrdU labeling, the cells were plated onto sterilized coverslips placed on the well bottoms in 12-well plates. PS1145-pretreated and control DU145 cell cultures were treated with BrdU (2 mg/ml) for 2 h. The coverslips with cells were fixed and permeabilized with acetone-methanol (1:1) mixture at À201 for 15 min, washed with PBS, blocked with 20% goat serum and stained with primary anti-BrdU Ab from Becton Dickinson (Franklin Lakes, NJ, USA) and secondary goat anti-mouse Ab conjugated with Cy3 (Jackson Immunoresearch laboratories Inc., West Grove, PA, USA). DAPI (Vector laboratories, Burlingame, CA, USA) was used to counterstain the nuclei. The number of BrdU-positive cells was counted in PS1145-treated and control cultures (10 fields of view in each sample). For quantitative analysis, the data were presented as the % of BrdU-positive nuclei to the total number of nuclei stained with DAPI.
Apoptosis detection
To evaluate apoptosis, we used Western blot analysis of PARP proteolysis and caspase 3/7 functional assay. To study PARP proteolysys, prostate cells, plated on 10 mm dishes, were treated with 10 mM PS1145 alone or in combination with 7.5 ng/ml TNF-a (R&D Systems, Minneapolis, MN, USA) for 16-72 h upon reaching 50% confluence. Adherent cells and detached floaters were combined for whole-cell protein extract preparations. PARP cleavage was estimated by Western blot analysis with anti-PARP antibody (Pharmingen, San Diego, CA, USA).
For caspase 3/7 functional assay, DU145 cells were plated at 5 Â 10 3 cells/well of a 24-well plate in 100 ml of complete media. PS1145 was added at increasing concentrations from 0.1 to 50 mM. Caspase activity was measured after 48 h treatment with PS1145 using ApoOne kit (Promega Corp., Madison, WI, USA) according to the manufacturer's protocol. In all, 100 ml of the substrate was added for 2.5 h.
Transwell
s invasion assays The PC-3 High Invasion subclone (PC3-S) was previously selected by serial passages through reconstituted basement membrane Matrigel s (Becton Dickinson, Lincoln Park, NJ, USA) in the Transwell s invasion apparatus (Lindholm et al., 2000) . For analysis of PC-3S cell invasion in the presence of PS1145 inhibitor, a Transwell s invasion assay was used according to the protocol described previously (Lindholm et al., 2000) . Prior to the invasion assay, the cells were preincubated with [ 3 H]thymidine and either PS1145 or control vehicle (Lindholm et al., 2000) overnight. The cells were incubated in the invasion chamber for up to 72 h. Invading cells were collected as described previously (Lindholm et al., 2000) , and the cell invasion was quantitated by counting the cell-associated c.p.m. The percent invasion was calculated by dividing the invading cell-associated c.p.m. to the total cellassociated c.p.m. The statistical analysis of percent invasion was determined by Student's t-test comparisons using InStatt statistical software (GraphPad Software, Inc., San Diego, CA, USA). The results are presented as mean7standard deviation (s.d.).
Immunostaining of prostate tissues
Prostate tissues were obtained from white male patients at the age 40-82 years during biopsy or surgery to remove prostate tumors. Paraffin sections of formalin-fixed PC samples with verified diagnosis were used for immunostaining. The immunostaining was performed using Envision þ System-HRP (DAB) kit according to the manufacturer's protocol (DakoCytomation, Carpenteria, CA, USA). After Ag retrieval in a pressure cooker (for 5 min at 20-25 psi) in citric buffer (pH 6.0), tissue sections were blocked with 20% goat serum in PBS, and consequently incubated with primary rabbit polyclonal Ab against phospho-IKKa/b (Cell Signaling Technology, Inc., Beverly, MA, USA), followed by secondary anti-rabbit IgGreagent provided with the Envision þ System-HRP (DAB) kit. Immunostaining was visualized with DAB chromogen (DakoCytomation, Carpenteria, CA, USA) and counterstained in Mayer's hematoxylin.
Data in all figures are shown as results of the representative experiments. All experiments were repeated at least three times.
Abbreviations EMSA, electrophoretic mobility shift assay; Erk, extracellular signal-regulated kinase; IAP, inhibitor of apoptosis; IKK, inhibitor of nuclear factor kappa-B kinase; IkB, inhibitor of nuclear factor kappa-B; IL, interleukin; LPS, lipopolysaccharide; MAPK, mitogen-activated protein kinase; Mek1/2, dualspecificity mitogen-activated protein kinase kinase 1; NF-kB, nuclear factor kappa-B; PC, prostate carcinoma; SAPK/JNK, stress-activated protein kinase/Jun-N-terminal kinase; TNF-a, tumor necrosis factor alpha.
